AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 251 min read$MRK

Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Merck and Daiichi Sankyo withdrew their US application for a lung cancer drug. The decision was announced on September 25, 2026, during after-hours trading. Merck's stock was up 0.54% at the time of the announcement.

Original reporting
marketscreener.com
Published Sep 25, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$MRK
Bearish
high confidence
Mentioned
$MRK
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$MRKBearishMed
01

Why it matters

Regulatory setback likely depresses near-term share prices and raises questions on pipeline timing.

02

Market read

Direct negative news for two listed pharma stocks; broader oncology sector may feel pressure.

03

What to watch

Potential for alternative regulatory pathways or partnerships outside the US.

Relevance 7/10Novelty 7/10Timing: after-hours today

Background

Both companies announced the withdrawal of a joint lung cancer drug's US filing.

Company-level read

Ticker impact

$MRKBearishHigh confidence
Context

Merck withdrew its US application for a lung cancer therapy, a new regulatory setback.

Expected impact

Downward pressure on MRK price in the short term.

Evidence & confidence

Regulatory withdrawal is a material adverse event for a pharma pipeline.

Market effects

Sector

May dampen sentiment for oncology pipeline stocks.

Regional

US biotech sector could see slight pullback.

Global

Limited to pharma/biotech investors.

Counterpoint

What could challenge this read

The withdrawal could free resources for more promising candidates, potentially benefiting long-term pipeline.

Key entities

  • Company
    Merck

    US pharmaceutical giant (ticker MRK).

  • Company
    Daiichi Sankyo

    Japanese pharma firm (ticker DSK).

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 26
$MRKHighAI 9/10

What Does Merck (MRK) FDA Approval In Advanced Kidney Cancer Mean?

Merck (MRK) and Eisai received FDA approval for Welireg plus Lenvima to treat advanced kidney cancer after prior immunotherapy. The approval is based on Phase 3 trial data. Merck, valued at $367.1b, aims to expand its oncology portfolio with this new regimen, positioning it against competitors like cabozantinib. Investors will watch how quickly the new treatment gains market share.

simplywall.st2 min
SEP 25
$MRKMedAI 8/10

Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling.

Merck and Daiichi Sankyo withdrew the Biologics License Application for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer. The decision follows discussions with the FDA, but enrollment continues in a phase 3 trial. The drug is a B7-H3 directed antibody drug conjugate being jointly developed by the companies. Both firms expressed disappointment but remain committed to evaluating the drug's potential in other cancer types.

stocktitan.net2 min
SEP 25
$MRKMedAI 8/10

Merck (MRK) Withdraws I-DXd Biologics License Application for ES

Merck (MRK) withdrew its BLA for I-DXd in treating extensive-stage small cell lung cancer, citing insufficient data for accelerated approval. The company remains committed to ongoing clinical trials. MRK's dividend yield is 2.31% with a high payout ratio of 1.11, and its stock is 23.2% overvalued relative to its GF Value. The company has a GF Score of 83, reflecting strong profitability and growth but valuation concerns.

gurufocus.com2 min
SEP 25
$MRKLow

Merck, Daiichi withdraw ifinatamab FDA application

Merck (MRK) and Daiichi Sankyo (4568) withdrew a U.S. FDA application for their small cell lung cancer drug ifinatamab deruxtecan, citing insufficient data. The Phase 2 trial showed a 54.8% response rate at a higher dose. The companies continue a Phase 3 trial, nearing full enrollment, with no new filing timeline provided.

mugglehead.com2 min
SEP 25
$MRKHighAI 9/10

Merck, Daiichi Sankyo withdraw US application for lung cancer therapy

Merck and Daiichi Sankyo withdrew their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan, after the FDA deemed the mid-stage clinical study data insufficient. The therapy was intended for treating extensive-stage small cell lung cancer in adults who had progressed after standard chemotherapy, according to the companies.

ksl.com2 min